Ketamine only
Phase 1Small molecule
Ketamine only is one of 8 small molecule programs targeting Major Depressive Disorder (MDD). It is currently in Phase 1.
1
Indications
5
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Major Depressive Disorder (MDD)
#DrugCompanyPhaseTrials
1Ketalar
Boehringer IngelheimApproved
CYB003
CCybin IRL Limited
Phase 3
Thiamine
UUniversiti Kebangsaan Malaysia Medical Centre
Phase 2
PET Scan With VAT
SStony Brook University
Phase 3
Celebrex
PPhiladelphia Eye Associates
Preclinical
DT-101
DDraig Therapeutics Ltd
Phase 2
SPT-300
SSeaport Therapeutics
Phase 2
Ketamine only
UUniversity of Pennsylvania
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Post Operative Pain1 trial
Low-Dose Ketamine Infusion for Post-Operative Pain in Patients Undergoing Laparoscopic Cholecyctectomy
Completed·—·Phase 1·NCT06966596·116 enrolled
Pediatric1 trial
Ketamine/Propofol vs Ketamine Alone for Pediatric Fracture Reduction
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT00490997·140 enrolled
Post Spinal Anesthesia Shivering1 trial
Long COVID1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ketamine only. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania